[Nasal-paranasal sinus polyposis].
1.
Nasosinusal polyposis and allergy must be considered as two distinct conditions. 2.
Approximately 1% of the general population has nasosinusal polyposis, a condition strongly associated with asthma (about one-third of the patients with polyposis have asthma). Patients with nasosinusal should undergo a complete respiratory examination in order to search for asthma or an asthma equivalent. 3.
Eosiophils play a crucial role in the inflammatory reaction, releasing almost all the known inflammatory mediators: cytokines, chemokines and growth factors. 4.
The epithelial cell probably plays a very important role. 5.


METHODS
Long-duration intranasal corticotherapy is the basis of drug treatment. Short courses of oral corticosteroids may be useful during acute episodes in inflammation. The exact effect of oral corticosterid is not clearly elucidated but it is known that non-steroidal antiinflammatory drugs (NSAID) are contraindicated in polyposis. 6.


METHODS
Surgery is reserved for medical failures or for patients with a contraindication for drug therapy. Endonasal ethmoidectomy is the basis treatment. 7.


CONCLUSIONS
Better understanding of the underlying pathophysiology and the probable genetic component will determine future treatments. Perspectives include antiinflammatory drugs currently reserved for other conditions (antileucotriene, antiTNFa, IL-18) and elaboration of new antiinflammatory drugs.
Crampette
L
L
D006801:Humans; D009297:Nasal Mucosa / Q000473:pathology; D009298:Nasal Polyps / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D009669:Nose Neoplasms / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D010255:Paranasal Sinus Neoplasms / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D011127:Polyps / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D012307:Risk Factors